All In Biotech

Drug Trial Radar · NCT01702428

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Consistency Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Healthy Children 12 to 15 Months of Age

Last checked: Nov 19, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,016 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,016

Actual

Start

Nov 9, 2012

Primary completion

Nov 25, 2014

Study completion Apr 16, 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 8, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate consistency in terms of the immune response to three different lots of GSK Biologicals' trivalent MMR vaccine manufactured to target potencies, and compare its immunogenicity to Merck \& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).

Conditions

  • Rubella
  • Measles
  • Mumps

Interventions

  • PriorixBiological

    Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.

  • M-M-R IIBiological

    Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.

  • VarivaxBiological

    Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.

  • HavrixBiological

    Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.

  • Prevnar 13Biological

    US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-valueTime frame: At Day 42
  2. Anti-measles Virus Antibody ConcentrationsTime frame: At Day 42
  3. Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-valueTime frame: At Day 42
  4. Anti-mumps Virus Antibody ConcentrationTime frame: At Day 42
  5. Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-valueTime frame: At Day 42
  6. Anti-rubella Virus Antibody ConcentrationTime frame: At Day 42
  7. Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value in Pooled MMR GroupsTime frame: At Day 42
  8. Anti-measles Virus Antibody Concentrations in Pooled MMR GroupsTime frame: At Day 42
  9. Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value in Pooled MMR GroupsTime frame: At Day 42
  10. Anti-mumps Virus Antibody Concentration in Pooled MMR GroupsTime frame: At Day 42
  11. Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value in Pooled MMR GroupsTime frame: At Day 42
  12. Anti-rubella Virus Antibody Concentration in Pooled MMR GroupsTime frame: At Day 42

Locations

90 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Dothan, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Fayetteville, Arkansas

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Daly City, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Hayward, California

  • GSK Investigational Site

    Los Gatos, California

  • GSK Investigational Site

    Mission Hills, California

  • GSK Investigational Site

    Paramount, California

  • GSK Investigational Site

    Pleasanton, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Santa Clara, California

  • GSK Investigational Site

    Walnut Creek, California

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Nampa, Idaho

  • GSK Investigational Site

    Evergreen Park, Illinois

  • GSK Investigational Site

    Ames, Iowa

  • GSK Investigational Site

    Augusta, Kansas

  • GSK Investigational Site

    Overland Park, Kansas

  • GSK Investigational Site

    Topeka, Kansas

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Bossier City, Louisiana

  • GSK Investigational Site

    Columbia, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Fall River, Massachusetts

  • GSK Investigational Site

    Niles, Michigan

  • GSK Investigational Site

    Stevensville, Michigan

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    Ithaca, New York

  • GSK Investigational Site

    Syracuse, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Erie, Pennsylvania

  • GSK Investigational Site

    Hermitage, Pennsylvania

  • GSK Investigational Site

    Sellersville, Pennsylvania

  • GSK Investigational Site

    Warwick, Rhode Island

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.